We bring “miracles in medicine” to make a better future (mirai) in people's lives.
ABOUT USINNOVATIVE NEOBIOLOGICS
We use a simple, elegant technology called LassoGraft Technology® to extend the boundaries of biopharmaceuticals, creating new, innovative Neobiologics (multifunctional biopharmaceuticals) and bringing them to those who need them.
Portfolio
We build up a rich, varied portfolio by applying LassoGraft Technology® to a wide variety of modalities and therapeutic areas.
PORTFOLIO
Science
LassoGraft Technology®, by grafting target-specific cyclic peptides onto any proteins in the body, transforms them into biologically active proteins, creating new biopharmaceutical Neobiologics.
SCIENCE- Speed
- Robustness and reliability
- Plug & Play
- Multifunctionality
Partnership
In drug development, we value collaboration with pharmaceutical companies. The essence of collaboration is to combine our partners’ drug development expertise and experience with our LassoGraft Technology®, to create cutting-edge biopharmaceuticals rapidly and deliver them to patients worldwide who need them.
PARTNERSHIPNews
ALL NEWS-
2023.05.10May 10: We have renewed our website.
-
2023.02.09Feb 9: Our founding director, Prof. Hiroaki Suga at the University of Tokyo, has been awarded the prestigious 2023 Wolf Prize in Chemistry.
-
2022.12.05Feb 1 [Japanese Only] Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo, have contributed an article on LassoGraft Technology in "Jikken Igaku Zokan Vol. 40 No. 20, Antibody Medicine Expands Therapeutic Possibilities" published by Yodosha.
-
2022.11.24Nov 24: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was introduced in the Nature biomedical engineering, “news & views” (Nat Biomed Eng, 24 Nov (2022). https://www.nature.com/articles/s41551-022-00974-3).
-
2022.11.07Nov 8: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was published in the Nature biomedical engineering (Nat Biomed Eng, 07 Nov (2022). https://doi.org/10.1038/s41551-022-00955-6).
-
2021.08.10Aug 10: Our Company entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (TSE First Section: Securities Code 4528) to create next-generation biopharmaceuticals using our proprietary LassoGraft Technology that integrates cyclic peptide discovery method (RaPID System) with protein engineering (PDF attached).